前苏联专利SU1192624A3 Method of producing naphthylidiene and quinoline compounds

专利PDF首页>>前苏联专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
There are disclosed compounds having the following general formula C: <CHEM> wherein X is N or CH and Z is galacturonic, aspartic, gluconic or glutamic acid; as well as processes for producing these compounds by reacting the acid Z with the other component. The acid addition salts of formula C are, unlike other acid addition salts of the active compound, suitable for parenteral administration when the active compound is used as an antibacterial agent.
公开号:SU1192624A3
申请号:SU823450276
申请日:1982-06-10
公开日:1985-11-15
发明作者:Фредерик Мич Томас
申请人:Варнер-Ламберт Компани (Фирма)；
IPC主号:

专利说明:

I: K) Breaching relates to a process for the preparation of new salts of naphthylidene and hiioline compounds of the general formula
where X is a nitrogen atom or a CH group; Z is galacturonic, aspartic, gluconic, or glutamic nova acid, provided that when Z is D-hapturonic acid, X cannot identify a nitrogen atom. The purpose of the invention is to obtain new naphthylidene and quinoline compounds with better characteristics required for parenteral administration into the body than known structural analogues of a similar effect.
The invention is illustrated by the following examples.
Example 1. L-Asparagate 1-ztil-6-fluoro-1, 4-dihydro-4-oxo-7- (1-piperazinyl) -1,8-naphthyridine-3-carboxylic acid.
A mixture of 199 mg (1.5 mmol) of L-acnaraginic acid, 480 mg (1.5 mmol of 1-methyl-6 fluoro-1,4-dihydro-4 oxo-7- (1-piperazinyl) -, 8 naphthyridine -3-carboxylic acid and 10 ml of water are heated to 60 ° C. The resulting solution is dried at a temperature below, resulting in 730 mg of a solid, 600 mg of this substance is crystallized from a solution of 2 ml of water and 4 ml of absolute ethanol. The crystals are filtered, washed with absolute ethanol and dried, resulting in a yield of 310 mg of the target product: T.Sh1. (decomposed) 214-215 C. (L) - 4.3 (s 2). Analysis shows This product contains 0.8 mol of water per mole of compound.
Example 2. L-Glutamate 1 ethyl 6-fluoro-1, 4-dihydro-4-oxo-7- (1-piperazinyl) -1,8-naphthyridine-3-carboxylic acid.
A mixture of 220 mg (1.5 mmol) of L-glutamic acid, 480 mg (1.5 mmol) of 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7926242
- (1-piperazinyl) -1,8-paftiridine-Z-carboxylic acid and 10 ml of water are heated to 60 C. The resulting solution is cooled at a temperature below OS, 5 resulting in a gain of 690 mg
solid matter. 620 mg of this solid crystallizes cosiness from a solution of 2 ml of water and 6 ml of absolute ethanol. Crystals filter-
10 are washed with absolute ethyl alcohol and dried, resulting in 484 mg of the desired product with so pl. (decomposition) 196-200 ° C. W -: 0.9 ° (c 2, HgO).
15 The assay indicates the presence of 0.6 mol of water per mole of compound.
Example 3. L-Asparagate I-ethyl-6-fluoro-1, 4-dihydro-4-oxo-7g- (1-piperazinyl) -3-quinolinecarboxylic
20 acids.
A mixture of 1.28 g (4 mmol of 1-ethyl-6-fluoro-1, 4-dihydro 4-oxo-7- (1-piperazinyl) -3-quinolinecarboxylic acid, 532 mg (4 mmol) of L-aspartic
25 acids and 30 ml of water are stirred at 40-50 ° C for 20 minutes and at room temperature for 2.5 hours. The solution is clarified by filtration and the filtrate is dried at
0 below O C, resulting in a gain of 1.77 g of a solid. This solid is crystallized from 6 ml of water and 20 ml of absolute ethanol. The crystals are filtered, washed with absolute ethanol and ether and dried, resulting in a yield of 1.11 g of the expected product with mp. (with simultaneous decomposition) 208 ° C.
0 (ot) p - 5.1 (s 2,).
The analysis shows a content of 0.8 mol of water per mole of compound.
Example 4. L-Glutamate 1-ethyl-6-fluoro-1,4-digi. , ro-4-oxo-7- (t-pi
5 per-vinyl) -3-quinolinecarboxylic acid. A mixture of 1.28 g (4 mmol) of 1-ethyl-l-fluoro-1, 4-dihydro-4-oxo-7- (1-piperazinyl) -3-quinolinecarboxylic acid, 538 mg (4 mmol) of L-glutamic acid and 50 ml of water is heated over a steam bath. The resulting solution is clarified by filtration, and the filtrate is lyophilized, resulting in
5 1.37 g of solid are obtained. This product is crystallized from 6 ml of water and 45 ml of absolute ethyl alcohol. The crystals are filtered, washed with absolute ethyl alcohol and ether, and dried, resulting in a yield of 1.39 g of the desired product with m.p. (with simultaneous decomposition) 184-185 ° С. () 1 + 1.3 ° (s 2,). The analysis shows a content of 0.1 mol of ethanol and 0.25 mol of water per mol of compound. Example 5. D-Galacturonate 1-eth1-6 fluoro 1,4 dihydrog4-oxo-7 - (1 - piperazinyl) -3 - quinolinecarboxylic acid A mixture of 1.28 g (4 mmol) of 1-ethyl 6-fluoro, 4 dihydro 4-oxo-7- (1-piper zinyl) -3-quinolinecarboxylic acid 817 mg (4 mmol) of hydrate B galactoral acid and 30 ml of water are stirred for 1.5 hours at room temperature. The solution is clarified by filtration, and the filtrate is dried at a lower temperature, resulting in 1.98 g of solid product. This product is crystallized from a solution of 7.5 water and 14 ml of absolute ethanol. The crystals are filtered, washed with absolute ethyl alcohol and ether and dried, resulting in a gain of 1.36 g of the target product with so pl. (with simultaneous decomposition) 142 C. (Di) + 8.4 (с 2, НгО). The analysis shows a content of 0.2 mol of ethyl alcohol and 0.15 mo of water per mol of compound. Example 6. D-Gluconate 1-ethyl-6-fluoro-1, 4-dihydro-4-oxo-7- (1-piperazinyl) -1,8-naphthyridine 3-carboxylic acid. A suspension of 2.78 g (8 mmol) of 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7- (1-piperazinyl) -1,8-naphthyridine-3-carboxylic acid one-and-a-half hydrate 1.21 ml (2.8 mmol) of 2.34 normal industrial solutions of D-gluconic acid and 60 ml of water are stirred at room temperature. After 12 hours, an additional 2.7 ml (6.3 mmol) of an aqueous solution of D-gluconic acid in water is added, and a yellow solution is formed within five minutes. This solution is clarified by filtration, and the filtrate is dried at a temperature below about C. The solid product is crystallized from a solution of about 10 ml of water and 40 ml of absolute ethanol. The crystal galls are stirred for 4 hours at room temperature, filtered, washed with absolute ethanol and ether, and dried, yielding 3.97 g of the desired product with mp. (with decomposition) 164-165 ° C. (o) + 4.9 (s 2,). The analysis shows a content of about 1 mole of water per mole of compound. Example 7. D-Gluconate 1- -ethyl-6-fluoro-1,4-dihydro-4-oxo-7- (1-piperazinyl) -3-quinolinecarboxylic acid. A. Suspension 2.7 g (8 mmol) of 1-ethyl-6-fluoro-1,4-dihydro-4-OXO-7- (1-piperazinyl) -3-quinoline-carboxylic acid monohydrate. 1.43 g (8 mmol) of 8-lactone D-gluconic acid and 60 ml of water are stirred at room temperature for 19.5 hours. The solution is clarified by filtration, and the filtrate is dried at a temperature below O C. The solid product is crystallized from solution about 10 ml of water and 50 ml of absolute ethyl alcohol. The crystals are filtered, washed with absolute ethyl alcohol and ether and dried, resulting in a gain of 3.56 g of the expected product with mp. 171-172 С (melting with decomposition) () i + 5.1 ° (с 2,). The analysis shows the content of O, 1 mol of water per mole of compound and the weak hygroscopicity of the product. B. Suspension of 0.98 g (2.9 mmol) of 1-ethyl-6-fluoro-1,4-dihydrr-4-oxo-7- (l-piperazinyl) nolincarboxylic acid monohydrate, 2.48 ml (2.9 mmol) of 1.17-normal D-gluconic acid in water obtained by diluting an industrial solution, and 20 ml of water are stirred at room temperature for 2 hours. The resulting yellow solution is clarified by filtration, and the filtrate is dried at a temperature below OC. The solid product is recrystallized from a solution of about 4 ml of water and 17 ml of absolute ethanol. The crystals are filtered, washed with absolute ethyl alcohol with ether and dried, resulting in a gain of 1.35 g of the product in the form of crystals:. square (with simultaneous decomposition; 165-168C. 5.7 (c 2, I O). (() i) g - t - 2 The analysis shows a content of about 0.2 mol per mole of the compound. D-gluconate salts derived from industrial gluconic acid solution (examples 6 B and 7 BJ, have more rapid decomposition temperatures than the corresponding salt obtained from D-gluconic acid 8-lactone. Gluconate salts obtained from industrial D-gluconic acid solution also have stronger staining (darker solutions are obtained than the corresponding salts derived from the 8-lactone D-glucanoic acid, therefore, the preparation of a gluconate salt using o-lactone D-gluconic acid is the preferred method for carrying out the invention. Table 1 presents the solubility data and pH values which demonstrate that most of the pharmaceutically acceptable salts derived from compounds A and B P-ethyl-6-fluoro-1J4 dihydro-4-oxo-7-1-pipera zinyl-3-quinolinecarboxylic acid and 1-ETHYL-6-Fluoro-1,4-dihydro-4-oxo-1 8- (1-piperazonyl -1,8-naphthyridine-3-carboxylic acid, respectively, cannot be used to prepare of pareyteralno introduced into the body of dosage forms containing these compounds. I The data given in table. 1, obtained in the implementation of the procedure for the selection of solubility. . A measured amount of Compound A and Compound B, calculated from the selected concentrations, is introduced into the volumetric flasks. Equal molar amounts of the added acid, amino acid or base are introduced into the volumetric flasks either as a solution or in dry form. De-ionized water is introduced to such a volume that pre-determined concentrations are achieved. All flasks are subjected to acoustic impact for 15 minutes, held at room temperature for 30 minutes, then the contents of the flask are filtered through a fused glass melted funnel. After adjusting the pH of the filtrate, the appropriate diluted solutions are introduced in 0.1N. HCl for ultraviolet spectrophotometric determination of the 4, 1 radio. Tenfold diluted solutions of the original filtrates are introduced into standard solutions (IV). These diluted solutions are analyzed, the precipitation is determined. The results of the effect of 10-fold dilution of the soluble forms of compounds A and B with standard solutions (IV) are given in Table. 3 and 4. When choosing a solubility first, the experiment was carried out to prepare solutions that should have a final concentration of compound A or compound B of about 25 mg / ml. Those acids and bases which do not impart sufficient solubility to the material to achieve a given concentration are considered unsuitable for this purpose. Acids and bases that may find useful applications are those acids and bases that are capable of forming solutions containing at least 150 mg / ml of Compound A or Compound B. These more concentrated solutions, which also have a pH value in the range of about 4 -8 are considered as solutions that have successfully passed selection procedures. The previously unpredictable properties of salts obtained from compounds A and B are dreams from the results presented in Table. 1. These properties are considered from the point of view of the requirements necessary to obtain parenterally administered dosage forms of the drug. Thus, for example, the hydrochloride of compound A has a satisfying solubility, but does not satisfy the required pH value, while the hydrochloride of compound B does not satisfy the solubility requirements, nor the pH value. The methanesulfonates and isothionates of both Compound A and Compound B show good solubility, but do not satisfy in terms of pH, as well as. both salts derived from L-cysteic acid. Acetate salts of both Compound A and Compound B can be used according to the present invention, but they are not well lyophilized. Therefore, their use is limited. From the data table. 1 it is clear that lacpata salts can be used, but in modern production conditions it is not possible to reproducibly obtain high-quality lactic acid, and therefore its use is impossible. The use of choline and sodium salts is excluded due to the pH value of their solutions not meeting the requirements.
Thus, it has been found that salts suitable for this purpose are galacturonic, aspartic, glutamic and gluconic acids, salts.
The data table. 2 confirm the results presented in table. one.
In tab. 2 summarizes the data for. using selected lyophilized and crystalline salts.
The following table. 3 and 4 relate to salts in standard solutions for intravenous infusion.
The compounds according to the invention are used to treat diseases caused by the following organisms: Staphylococcus (Staphylococcus) Streptococci (Streptococcus) Halmophilus,
Sample solubility data
Neisseria, Clostridium, Enterobac ter, Escherechia, Klebsiella, Proteus, Providencia, Pseudomonas,
Serratia. Although the salts covered by the invention may be administered to the patient through the mouth of the patient, it is desirable to administer them parenterally with a dose that varies depending on the requirements and
patient tolerance. Of the various methods for administering the drug itself, the intravenous method is preferred. The generally accepted dose limit of a drug administered to a human body weighing 70 kg is from about .70 mg to 21 g per day (from 1 mg to 300 mg per kg patient weight per day, preferably from 210 mg to 6.3 g
day (from 3 mg to 90 mg per kg of patient weight per day, if desired, this dose of the drug can be divided into portions.
In tab. 5-10 illustrate the antibacterial effect of compounds corresponding to the invention both in vitro and in vivo conditions when performing standard tests.
Table
1.5
3.5
19.8
45.1
46.5
128

182 d
201
235
166
but
175 оВс1
3.14
1,3
3.46 77.7 2.8
1.76 7.75
2.60 99 75
3.6
4.45 168 7
4.6
1.83
195
4.97
4.78 155 211
1.67
Isotionov
Milky
Glshdinova
and, L-Alaninova
B-phenylalaninov
L-Leucine
L-Giscioninova
L-Tryptophanova
L-Prolinova
L-Serinova
L-Lizinova
L-Argininov
L-Asparaginova
B Glutamine
L-Cysteine
/. ethanolamine
Choline
Sodium hydroxide d Commercially available salt-making solution. Solubility of lyophilized and
1) -Galakturonov 256 183 4.0 4.9
Dairy 256183 4.6 5.15
220
1.35
1.01 4.05
217 1.2 4.24 6.14 6.87 6.44 3.4 7.76 6.3 1.5 6.8 6.2 1.1 6.9, 7, A 1.1 7.53 6.65 2.0 7.08 6.28
1. 6.92 6.24 1.3 6.70 9.5
4.3 9.4 6.7 9.8 9.7 4.88 165 4.64 5.08 160 4.98 221 2.92 2.78 9.68
, 3 9.7 36.2, 34 9.8 10.5 75, 0 gluconic acid, used Table 2 crystalline solids
eleven
Concentrations are not necessary maximums, for
except hydrochloride.
S-lactone gluconic acid is used to prepare the salts.
12
1192624 Continuation of table 2
ft
Tj
X
e; “)“ I
H
sr
"A to | 1-1 mapping
Compound A60.1 0.1 0.2 OO, 1 Aspartic salt 0.1 0.1 0, 1 acid
Glutanin salt
acid 0.1 0.1 0.1 0.1 0.1 1.6 0.1 1.6 1.6 1.6 0.8
Gluconate 0.2 0.2 0.2, 1 0.2 1.6 0.2 0.8 1.6 1.6 - 0.8
Galacturon salt
acid 0.1 0.1 0.1 60.1 0.1 0.8 60.1 1.6 1.6 0.8
Based on the content of compound A Comparison of the antibacterial effect of compound B and its salts
Compound B0.2 0.2 0.2 0.1 0.1 Salt aspartic acid 0.2 0.1 0.1 0.1 0.1 acid Salt glutamic acid 0.2 0.1 0.2 0.1 0.1 Gluconate 0.4 0.1 0.2 0.2
Based on the content of compound B.
Comparison of the antibacterial effect of compound A with its gluconate salt upon subcutaneous administration of the preparation (Sc) in the course of the standard test of these compounds for their protective action carried out on bacteria with a strong bacterial infection
Single dose S {C) PDyo (mg / kg) + 95%
Connection of permissible limits
Escherichia coli vogel A 1, 3 + 0.3 Klebsiella pneumonial MGH-2 Gluconate 1.4 + 0.3. , Single dose of medication given
mcg / mp
Table 6
M1C, mcg / ml
Table 7
-2 Escherichi; , 7119262418 antibacterial action of compound A and its salts Table 5 0.4 1.6 0.1 1.6 0.8 0.8 0.8 60.1 0.8 X0.0 0.6 1.6 0.8 0, 8 3,1 0,2 1,6 3,1 3,1 0,4 3,1 0,1 3,1 3,1 6,3 0,2 1,6 1,6 0,1 3,1 3,1 6 3 0,8 1,6 0,4 3,1 3,1 3,1 0,5 + 0,1 0,5 + 0,1 time of infection.
Comparison of the antibacterial effect of compound A with its gluconate salt upon administration of the drug through the mouth (PO) in the course of the standard test of Darga compounds for their protective action carried out on bacteria with a strong bacterial infection
15 + 3
A 13 + 6 Gluconate
Single dose of the drug given during infection.
Comparison of the antibacterial effect of compound B with its salts upon subcutaneous administration of the preparation (si) in the course of the standard test of these compounds on them. protective effect on bacteria with strong bacterial contamination
Single dose of medication administered during infection.
Comparison of the antibacterial effect of compound B with its salts upon administration of the drug through the mouth (RO) in the course of a standard test for their protective effect on mice with strong bacterial
contamination
14 + 7.0
13 + 3.0
Table 8
3.3 + 0.5 3.9 + 0.9
Table 9
Table 10
3.1 + 0.7
2.9 + 1.0 Glutamic acid salt 12.0 + 3.0 Gluconate + a), Single dose of medication given at 2.9 + 1.0 2.9 + 0.7 infection.

权利要求:
Claims (1)
[1]
METHOD FOR PRODUCING NAPHTHYLIDENE AND CHINOLINE COMPOUNDS of the general formula where X is a nitrogen mouth or a CH group;
Z is D-galacturonic, L-asparagus · new, D-gluconic or L-glutamic acid, provided that when Z is D-ra-lacturonic acid, X cannot mean a nitrogen atom, characterized in that the compound has the general formula where X has the indicated value is subjected to interaction with the specified acid Z.
Featured Priority
11.06.81 all of these signs, except for Z - D-gluconic acid;
12/24/81 at Z - D-gluconic acid.
as) SU Mon 1192624

类似技术:

公开号 | 公开日 | 专利标题

SU1192624A3|1985-11-15|Method of producing naphthylidiene and quinoline compounds

CS235502B2|1985-05-15|Method of 1-ethyl or vinyl-6-halogen-1-4-dihydro-4-oxo-7- |-1,8-naphtyridin-3-carboxyl acid production

SU1588282A3|1990-08-23|Method of producing derivative of quinoline or its pharmaceutically acceptable ester, or their salts

EP0493608B1|1995-10-04|Quinolonecarboxylic acid derivative

SU1598873A3|1990-10-07|Method of producing derivatives of quinoline or their pharmaceutically acceptable esters or acid-additive salts

IE49740B1|1985-12-11|Novel 1-aryl-2-acylamido-3-fluoro-1-propanols,their preparation and pharmaceutical compositions containing them

HU194735B|1988-03-28|Process for preparing hydro-basic pharmaceutical compositions containing quinolone-carboxylic acide derivatives

JP3726291B2|2005-12-14|Benzoxazine compound having stable crystal structure and process for producing the same

EP1492535B1|2005-10-26|Anhydrous crystalline forms i and ii of 1-cyclopropyl-6-fluoro-8-methoxy-7-| 4-oxo-1, 4-dihydroquinoline-3-carboxylic acid |

KR900006741B1|1990-09-20|Azetidinyl quinolone carboxylic acids and esters

WO2005070892A1|2005-08-04|Amine salt of carbostyril derivative

DE2914258A1|1979-10-25|PIPERAZINYLBENZOHETEROCYCLIC COMPOUNDS, METHODS OF PREPARING THEREOF, AND AGENTS CONTAINING THEM

FI110777B|2003-03-31|Process for selectively obtaining a 3/2-hydrate of 7- [7- | -amino-5-azaspiro [2.4] heptan-5-yl] -8-chloro-6-fluoro-1 - [| -2-fluorocyclopropyl] -4-oxo-1,4-dihydroquinoline-3-carboxylic acid

EP0702672B1|2000-09-06|Substituted quinoline derivatives and their use as inhibitors of gastric acid secretion

US6492391B1|2002-12-10|Crystal modification d of 8-cyano-1-cyclopropyl-7-|-6-fluoro-1,4- dihydro-4-oxo-3-quinolinecarboxylic acid

WO1993024460A1|1993-12-09|5-aminoquinolonecarboxylic acid derivative and antibacterial containing the same as active ingredient

EP2502626B1|2015-06-03|Crystalline levofolinic acid and process for its preparation

EP0364943A2|1990-04-25|Benzoheterocyclic compounds

EP0339406A1|1989-11-02|Quinoline-3-carboxylic acid derivatives, process for preparing the same, and composition exhibiting excellent antibacterial effect containing the same

EP0179239A2|1986-04-30|7-|-/-alkyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid having antibacterial activity and preparation thereof

US5556863A|1996-09-17|Compound for gastric acid secretion inhibition

EP0200527A2|1986-11-05|Norfloxacin salt

SU1056616A1|1989-07-15|Iodomethylates of 3-aminoderivatives of 1,5-dihydropyridazino-| quinoxaline having antituberculosis activity in vitro

WO1992016521A1|1992-10-01|Novel fluorine-containing quinolones and process for their preparation

JPH0641084A|1994-02-15|5-aminoquinolonecarboxylic acid derivative and antimicrobial agent containing the same derivative as active component

同族专利:

公开号 | 公开日

IL66027D0|1982-09-30|

ES512969A0|1983-02-16|

NO157739B|1988-02-01|

NZ200908A|1984-09-28|

IL66027A|1986-02-28|

EP0067666B1|1985-10-30|

GR77194B|1984-09-11|

FI78292C|1989-07-10|

KR880002087B1|1988-10-15|

DK155998B|1989-06-12|

DD202561A5|1983-09-21|

FI78292B|1989-03-31|

PH19091A|1985-12-19|

DK261582A|1982-12-12|

HU188181B|1986-03-28|

EP0067666A1|1982-12-22|

AU551596B2|1986-05-08|

NO821931L|1982-12-13|

IE53259B1|1988-09-28|

CA1191842A|1985-08-13|

DK155998C|1989-11-06|

AU8475782A|1982-12-16|

NO157739C|1988-05-11|

DE3267135D1|1985-12-05|

FI822066A0|1982-06-10|

KR840000544A|1984-02-25|

IE821390L|1982-12-11|

ES8304117A1|1983-02-16|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

AR223983A1|1978-08-25|1981-10-15|Dainippon Pharmaceutical Co|A PROCEDURE FOR PREPARING 6-HALOGEN-4-OXO-7- -1,8-NAFTIRIDIN-3-CARBOXYLIC ACID DERIVATIVES|

ZA811304B|1980-03-11|1982-06-30|Warner Lambert Co|Pharmaceutical salts of 4'-methanesulfon-m-anisidide|DE3318145A1|1983-05-18|1984-11-22|Bayer Ag, 5090 Leverkusen|7-AMINO-1-CYCLOPROPYL-6,8-DIFLUOR-1,4-DIHYDRO-4-OXO-3-CHINOLINE CARBONIC ACIDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR CONTAINING ANTIBACTERIAL AGENTS|

DE3333719A1|1983-09-17|1985-04-04|Bayer Ag|SOLUTIONS MILK ACID SALTS OF PIPERAZINYL CHINOLONIC AND PIPERAZINYL AZACHINOLONE CARBONIC ACIDS|

IT1196051B|1984-03-16|1988-11-10|Schiena Ricerche|ANTIBACTERIAL ACTIVITY COMPOUNDS|

DE3517709A1|1985-01-05|1986-07-10|Bayer Ag|BASIC PREPARATIONS OF CHINOLON CARBON ACIDS|

US4657913A|1985-04-18|1987-04-14|Warner-Lambert Company|Trifluoro- quinoline -3- carboxylic acids and their use as anti-bacterial agents|

DE3525335A1|1985-07-16|1987-01-22|Bayer Ag|EMBONATES OF CHINOLON CARBONIC ACIDS AND THEIR DERIVATIVES|

DE3537761A1|1985-10-24|1987-04-30|Bayer Ag|INFUSION SOLUTIONS OF 1-CYCLOPROPYL-6-FLUOR-1,4-DIHYDRO-4-OXO-7--QUINOLINE-3-CARBONIC ACID|

IT1196429B|1986-07-01|1988-11-16|Mediolanum Farmaceutici Srl|PROCESS FOR THE PREPARATION OF PYRID BENZOTIAZINS FOR ANTIBACTERIAL ACTIVITY AND THEIR SALTS WITH SULPHONIC ACIDS|

IL80459A|1986-10-30|1991-04-15|Abic Ltd|Water-soluble adduct of norfloxacin and nicotinic acid|

US5188833A|1987-12-28|1993-02-23|Kyorin Seiyaku Kabushiki Kaisha|Freeze-dried pharmaceutical preparations for parenteral use|

US4948894A|1989-02-21|1990-08-14|American Cyanamid Company|8-fluoro and 7, 8, 10-trifluoro-9--6-oxo-6H-benzo-quinolizine-5-carboxylic acids|

KR0159540B1|1992-01-21|1998-12-01|김정순|The salt of quinolone carboxylic acid and their pharmaceutical composition containing them|

ES2127036B1|1994-03-21|1999-11-16|Ind Quimica Agropecuaria S A|NORFLOXACINE ADDUCT SOLUBLE IN WATER.|

ES2088742B1|1994-06-29|1997-03-16|Salvat Lab Sa|ANTIBIOTIC COMPOSITION OF OTIC APPLICATION.|

DE19500784A1|1995-01-13|1996-07-18|Bayer Ag|Enrofloxacin solutions for injection or infusion|

MA24500A1|1997-03-21|1998-10-01|Lg Life Sciences Ltd|CARBOXYLIC ACID SALT DERIVATIVE FROM NAPHTHYRIDINE.|

ES2436140T3|2007-04-13|2013-12-27|Dong Wha Pharmaceutical Co., Ltd.|1-Cyclopropyl-6-fluoro-7--4-oxo-1,4-dihydro- [1,8] acid aspartate naphthyridine-3-carboxylic acid, preparation process thereof and antimicrobial pharmaceutical composition comprising the same|

法律状态:

优先权:

申请号 | 申请日 | 专利标题

US27260181A| true| 1981-06-11|1981-06-11|

US33418281A| true| 1981-12-24|1981-12-24|

[返回顶部]